[go: up one dir, main page]

CR8341A - Una composicion y metodo de tratamiento para condiciones urogenitales - Google Patents

Una composicion y metodo de tratamiento para condiciones urogenitales

Info

Publication number
CR8341A
CR8341A CR8341A CR8341A CR8341A CR 8341 A CR8341 A CR 8341A CR 8341 A CR8341 A CR 8341A CR 8341 A CR8341 A CR 8341A CR 8341 A CR8341 A CR 8341A
Authority
CR
Costa Rica
Prior art keywords
composition
treatment method
urogenital conditions
urogenital
conditions
Prior art date
Application number
CR8341A
Other languages
English (en)
Inventor
P Catania Anna
m lipton James
Original Assignee
Zengen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zengen Inc filed Critical Zengen Inc
Publication of CR8341A publication Critical patent/CR8341A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polymerisation Methods In General (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se relaciona con el campo del tratmiento para condiciones urogenitales.
CR8341A 2003-09-08 2006-04-07 Una composicion y metodo de tratamiento para condiciones urogenitales CR8341A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/659,053 US7402559B2 (en) 1999-03-24 2003-09-08 Composition and method of treatment for urogenital conditions

Publications (1)

Publication Number Publication Date
CR8341A true CR8341A (es) 2007-06-08

Family

ID=34312692

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8341A CR8341A (es) 2003-09-08 2006-04-07 Una composicion y metodo de tratamiento para condiciones urogenitales

Country Status (10)

Country Link
US (1) US7402559B2 (es)
EP (1) EP1667703A4 (es)
JP (1) JP2007505045A (es)
CN (1) CN1867349A (es)
AU (1) AU2004272049A1 (es)
CA (1) CA2542303A1 (es)
CR (1) CR8341A (es)
EC (1) ECSP066494A (es)
WO (1) WO2005025503A2 (es)
ZA (1) ZA200602144B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8864730B2 (en) 2005-04-12 2014-10-21 Rochester Medical Corporation Silicone rubber male external catheter with absorbent and adhesive
US20110171195A1 (en) * 2007-06-15 2011-07-14 Duke University Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
WO2009062604A2 (en) * 2007-11-02 2009-05-22 Magnus Von Knebel Doeberitz Compounds and methods associated with differential methylation of human papilloma virus genomes in epithelial cells
CN101947148A (zh) * 2010-10-11 2011-01-19 中国人民解放军第三军医大学第三附属医院 阴茎感觉增强装置
RU2452490C1 (ru) 2010-12-27 2012-06-10 Виктор Вениаминович Тец Лекарственное средство с активностью против семейства герпес-вирусов
US9707375B2 (en) 2011-03-14 2017-07-18 Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc. Catheter grip and method
US10092728B2 (en) 2012-11-20 2018-10-09 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Sheath for securing urinary catheter
US9872969B2 (en) 2012-11-20 2018-01-23 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Catheter in bag without additional packaging
RU2530587C1 (ru) * 2013-06-07 2014-10-10 Виктор Вениаминович Тец Способ лечения заболеваний кожи и слизистых оболочек, вызываемых вирусами простого герпеса 1-го и 2-го типов
JP6623216B2 (ja) 2014-08-26 2019-12-18 シー・アール・バード・インコーポレーテッドＣ Ｒ Ｂａｒｄ Ｉｎｃｏｒｐｏｒａｔｅｄ 尿道カテーテル
RU2605602C1 (ru) 2015-09-15 2016-12-27 Общество с ограниченной ответственностью "Новые Антибиотики" Способ получения натриевой соли (2,6-дихлорфенил)амида карбопентоксисульфаниловой кислоты
MX2020002752A (es) 2017-09-19 2020-07-20 Bard Inc C R Dispositivo puente de cateter urinario, sistemas y metodos de estos.
CN112451654A (zh) * 2020-12-10 2021-03-09 兆科药业（广州）有限公司 司来普伐肽的新用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH422813A (de) 1960-11-17 1966-10-31 Ciba Geigy Verfahren zur Herstellung neuer Polypeptide
CH444178A (de) 1963-05-20 1967-09-30 Ciba Geigy Verfahren zur Herstellung von B-MSH
JPS5921613A (ja) 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
US5157023A (en) 1984-08-21 1992-10-20 Lipton James M Antipyretic and anti-inflammatory lys pro val compositions and method of use
US5028592A (en) 1986-08-08 1991-07-02 Lipton James M Antipyretic and anti-inflammatory peptides
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
KR900005903B1 (ko) 1986-02-03 1990-08-16 유니버시티 페이턴츠 아이엔씨 알파-msh의 동족체의 국소적용으로 메라노싸이트를 자극시키는 방법 및 이에 사용될 수 있는 조성물
JPH02500361A (ja) 1986-08-08 1990-02-08 ボード、オブ、リージェンツ　ザ、ユニバーシティー、オブ、テキサス、システム 解熱及び抗炎症性ペプチド類
ATE125548T1 (de) 1988-03-28 1995-08-15 British Tech Group Peptide.
JP2514249B2 (ja) * 1989-05-23 1996-07-10 帝人株式会社 安定化されたカルシトニン類医薬組成物
JPH0674209B2 (ja) * 1990-09-17 1994-09-21 旭化成工業株式会社 カルバ型カルシトニン類水溶液注射剤の安定化方法
WO1993001211A1 (en) 1991-07-05 1993-01-21 Peptide Technology Limited Peptide which abrogates tnf and/or lps toxicity
JP3628713B2 (ja) 1993-06-07 2005-03-16 帝國製薬株式会社 生理学的に活性なペプチドを含有する膣投与製剤
JP2500361B2 (ja) 1993-07-14 1996-05-29 工業技術院長 温熱感評価用感覚エレメント
DE4340781C3 (de) * 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
JP3812957B2 (ja) * 1994-08-02 2006-08-23 森永乳業株式会社 角膜損傷治療剤
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US6001812A (en) 1995-04-28 1999-12-14 Societe L'oreal S.A. Modulating body/cranial hair growth with derivatives of the α-type melanocyte-stimulating hormone
FR2733421B1 (fr) 1995-04-28 1997-06-06 Oreal Utilisation de derives de l'hormone stimulatrice des melanocytes de type alpha pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
FR2738746B1 (fr) 1995-09-19 1997-11-14 Oreal Utilisation d'au moins un peptide dans une composition cosmetique ou pour la preparation d'un medicament
FR2778558B1 (fr) 1998-05-12 2001-02-16 Oreal Utilisation d'inhibiteur de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute
FR2781157B1 (fr) 1998-07-15 2000-08-25 Oreal Composition anti-inflammatoire
FR2784028B1 (fr) 1998-10-01 2003-02-07 Oreal Utilisation d'un peptide prevenant les reactions d'intolerance de la peau, notamment dans des compositions cosmetiques
AU767756C (en) 1999-01-22 2004-08-12 Schepens Eye Research Institute, Inc., The Activation of regulatory T cells by alpha-melanocyte stimulating hormone
US6800291B1 (en) * 1999-03-24 2004-10-05 Zengen, Inc. Uro-genital condition treatment system
CA2368387A1 (en) * 1999-03-24 2000-10-12 Anna Pia Catania Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
US6803044B1 (en) * 1999-03-24 2004-10-12 Zengen, Inc. Antimicrobial and anti-inflammatory peptides for use in human immunodeficiency virus
US7244710B2 (en) * 2002-05-21 2007-07-17 Zengen, Inc. Treatment of ophthalmic infections using antimicrobial peptides
US6780838B2 (en) 2001-01-29 2004-08-24 Zengen, Inc. Compounds for treating fungal pathologies of the oral cavity
US6894028B2 (en) * 2001-04-06 2005-05-17 Zengen, Inc. Use of KPV tripeptide for dermatological disorders
US7115574B2 (en) * 2001-12-10 2006-10-03 Zengen, Inc. System and method for support legacy operating system booting in a legacy-free system

Also Published As

Publication number Publication date
WO2005025503A2 (en) 2005-03-24
US7402559B2 (en) 2008-07-22
US20050037032A1 (en) 2005-02-17
AU2004272049A1 (en) 2005-03-24
ECSP066494A (es) 2006-11-24
EP1667703A4 (en) 2009-07-29
WO2005025503A3 (en) 2005-09-22
ZA200602144B (en) 2007-08-29
CA2542303A1 (en) 2005-03-24
CN1867349A (zh) 2006-11-22
EP1667703A2 (en) 2006-06-14
JP2007505045A (ja) 2007-03-08

Similar Documents

Publication Publication Date Title
DE602007012559D1 (de) H die schleimhaut
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
ECSP045429A (es) Combinacion de compuestos organicos
UY28252A1 (es) Compuestos de benzopirano útiles para tratar estados inflamatorios
CY1119002T1 (el) Αναλογα πολυαιθερα δεσφεριθιοκινης
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
HN2003000094A (es) Indazoles subtituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
CR10347A (es) Anticuerpos contra el peptidob-amiloide
MX2009005004A (es) Microorganismos o fracciones de los mismos capaces de activar inmunidad celular contra carbohidratos.
MX346822B (es) Pro-drogas de compuestos de 2,4-pirimidindiamina y sus usos.
EA201070247A1 (ru) Ингибиторы протеасом
BRPI0414599A (pt) pirrol-indóis substituìdos
CR8341A (es) Una composicion y metodo de tratamiento para condiciones urogenitales
MY142988A (en) Novel aminobenzophenone compounds
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
UY27774A1 (es) Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona
EA200600465A1 (ru) Ингибиторы каспазы, содержащие изоксазолиновый цикл
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
PA8650801A1 (es) Composiciones y formulaciones de ecteinascidina, como la ecteinascidina 743
ATE425982T1 (de) Thienopyrimidin-derivate als kaliumkanal- inhibitoren
ATE471324T1 (de) Triazolophthalazine
NI200300045A (es) Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
CR8545A (es) Piperidinilcarbonil-pirrolidinas y su empleo comoagonistas de melanocortina
EA201170201A1 (ru) Предотвращение и лечение радиационного поражения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)